Introduction {#s1}
============

The [Reproducibility Project: Cancer Biology](https://osf.io/e81xl/wiki/home/) (RP:CB) is a collaboration between the [Center for Open Science](https://centerforopenscience.org/) and [Science Exchange](https://www.scienceexchange.com/) that seeks to address concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology ([@bib7]). For each of these papers a Registered Report detailing the proposed experimental designs and protocols for the replications was peer reviewed and published prior to data collection. The present paper is a Replication Study that reports the results of the replication experiments detailed in the Registered Report ([@bib17]) for a paper by Liu et al., and uses a number of approaches to compare the outcomes of the original experiments and the replications.

Many cancers contain a subset of cells, termed cancer stem cells (CSCs), that are less differentiated and contribute to tumor progression and metastasis in various cancers ([@bib14]; [@bib32]). In 2011, Liu et al., reported that the microRNA miR-34a suppressed prostate CSCs via the adhesion molecule CD44 ([@bib19]). miR-34a was reported to be repressed in CD44^+^ prostate CSCs, below levels of let-7b, a previously reported tumor suppressive microRNA ([@bib20]; [@bib19]). Enforced expression of miR-34a, such as through lentiviral infection of the prostate cancer cell line LAPC4, inhibited tumor regeneration ([@bib19]). CD44 was also reported to be a direct and functional target of miR-34a, suggesting a key role of miR-34a in regulating prostate CSCs ([@bib19]).

The Registered Report for the paper by Liu et al. described the experiments to be replicated (Figures 1B, 4A and D and Supplemental Figures 4A,B and 5C), and summarized the current evidence for these findings ([@bib17]). Since that publication additional studies have reported tumor suppressive functions of miR-34a in other types of cancers. This includes inhibition of cellular proliferation and invasion in endometrial cancer by miR-34a through downregulating Notch1 ([@bib37]), inhibition of cellular migration and invasion in hepatocellular carcinoma via sirtuin 1 ([@bib41]), inhibition of cellular proliferation and clonogenicity of breast CSCs by directly preventing RNA 2',3'-Cyclic Phosphate and 5'-OH Ligase accumulation ([@bib18]), inhibition of proliferation and migration of gastric cancer cells through CD44 suppression ([@bib11]), and inhibition of tumor growth in non-small cell lung cancer with a combination of miR-34a and let-7 ([@bib12]). In addition to miR-34a, miR-141 was identified to suppress prostate CSCs by targeting a cohort of pro-metastasis genes including *CD44* ([@bib21]). Similar to miR-34a, miR-141 was underexpressed in CD44^+^ prostate CSCs, inhibited tumor regeneration when expressed in prostate cancer cell lines, and regulated *CD44* through a putative miR-141 binding site in the 3'UTR of *CD44* ([@bib21]). In addition, miR-34a delivered via a nanoparticle (MRX34) has been tested in a clinical trial to treat patients with unresectable primary hepatocellular carcinoma or individuals with unresectable liver metastasis ([@bib3]); however, the trial was terminated after five immune related serious adverse events (ClinicalTrials.gov identifier: [NCT01829971](https://clinicaltrials.gov/ct2/show/NCT01829971)). There have also been numerous studies reporting the utility of miR-34a as a biomarker, along with other biomarkers, to increase the sensitivity of detection in breast cancer ([@bib40]) and oral cancer ([@bib28]).

![miR-34a expression in CD44 populations.\
LAPC4 cells purified from xenograft tumors were sorted into CD44^+^ and CD44^-^ populations by fluorescence-activated cell sorting. (**A**) Percent expression of let-7b or miR-34a (normalized to miR-103) was determined by qRT-PCR for both populations. For each microRNA, expression levels in CD44^+^ cells were made relative to CD44^-^ cells, such that if expression was equal it would be assigned a value of 100% (indicated by dashed line). Means reported from one biological repeat. Note, let-7b expressed at 0.20%. Data from the representative experiment reported in Figure 1B of [@bib19] is displayed as a single point (red circle) for comparison. (**B**) Relative expression levels of let-7b or miR-34a (normalized to miR-103) are presented for CD44^-^ and CD44^+^ populations. Expression levels were made relative to let-7b in CD44^+^ cells which were assigned a value of 1. This is the same experiment as part (**A**), which is from one biological repeat. Additional details for this experiment can be found at [https://osf.io/tkn6c/](https://osf.io/tkn6c/.).](elife-43511-fig1){#fig1}

The outcome measures reported in this Replication Study will be aggregated with those from the other Replication Studies to create a dataset that will be examined to provide evidence about reproducibility of cancer biology research, and to identify factors that influence reproducibility more generally.

Results and discussion {#s2}
======================

For this study, we obtained a sample of androgen dependent LAPC4 cells from the authors of the original study. Interestingly, while the short tandem repeat (STR) profile of these cells was a partial match with the LAPC4 profiles in the DSMZ and Cellosaurus ([@bib1]) databases, it was not a match for the amelogenin locus, which is used in sex determination ([Table 1](#table1){ref-type="table"}). Instead of containing the X and Y alleles as expected, these cells only contained the X allele. This could have been due to random amplification failure (i.e. allelic dropout) or deletion of the Y allele ([@bib26]; [@bib38]). However, these cells also did not form tumors when injected into male NOD/SCID mice as described in Protocol 1 of the Registered Report. We obtained another sample of cells, but this time from the authors who originally isolated the LAPC4 cell line ([@bib16]). These cells had a partial match with the database profiles for LAPC4 cells, including the X and Y alleles for the amelogenin locus ([Table 1](#table1){ref-type="table"}), and, importantly, formed tumors when implanted into mice. Thus, we used these LAPC4 cells for the experiments described below.
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###### STR profiles.

LAPC4 cells provided by authors of the original study ([@bib19]) and authors who originally isolated the LAPC4 cell line ([@bib16]) underwent STR analysis for the indicated markers. The STR profiles for LAPC4 cells from databases are also provided for comparison (ATCC; [@bib34]; DSMZ).

  Marker       Liu           Klein         ATCC         Van bokhoven   DSMZ
  ------------ ------------- ------------- ------------ -------------- ------------
  Amelogenin   X             X,Y           X,Y          X,Y            X,Y
  CSF1PO       11,12         12,13         12,13        12,13          12,13
  D13S317      10,12         10,11,12      9,10,11,12   10,12          9,10,11,12
  D16S539      9             9             9            9              9
  D5S818       11,13         11,13         12           11,13          12
  D7S820       10.3,11       11,12         10,10.3,11   11             10,10.3,11
  TH01         6,9.3         6,9.3         6,9.3        6,9.3          6,9.3
  TPOX         8             8,9           8            8              8
  vWA          16            16,17,18      15,16        16             15,16
  D18S51       14,21,22      15,21,22      14,15,22     14,15,22       
  D21S11       28,30         28,29,30,31   28,30        28,30          
  D3S1358      15,16,17      15,17,18      15,17        15,17          
  D8S1179      13            13,14         13           13             
  FGA          21,22,23,24   21,22         21,22        21,22          
  D19S433      13,14,16      12,14,15                                  
  D2S1338      17,18,19      17,18,19                                  
  Penta D      10            9                                         
  Penta E      12,13         12,13                                     
  D12S391                    20                                        
  D6S1043                    12,13                                     

Expression of miR-34a in LAPC4 cells {#s2-1}
------------------------------------

We independently replicated an experiment to determine miR-34a expression in CD44^+^ and CD44^-^ LAPC4 cells. This experiment is comparable to what was reported in Figure 1B of [@bib19] and described in Protocol 3 in the Registered Report ([@bib17]). While the original study included other prostate cancer cell lines, this replication attempt was restricted to LAPC4 cells. LAPC4 cells purified from xenograft tumors were sorted into CD44^+^ and CD44^-^ populations by fluorescence-activated cell sorting (FACS). However, while the original study, and the described protocol in the Registered Report, described the top 10% most brightly stained cells to be defined as CD44^+^ and the bottom 10% most dimly stained cells as CD44^-^, we observed that the CD44 signal was weak without a clear division between positive and negative populations ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Additionally, the CD44 stained cell population was largely indistinguishable from cells stained with an isotype control antibody. Importantly, the isotype control and CD44 antibodies were matched on heavy chain, subclass, light chain class, fluorochrome type, fluorochrome ratio, manufacturing process, and formulation, which are known factors that impact the usability of the isotype control in flow cytometry ([@bib10]; [@bib24]). We also confirmed the CD44 antibody was able to successfully detect CD44^+^ human peripheral blood mononuclear cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Considering the weakly positive sample, CD44^+^ cells were defined as the top 1% of the population with the remaining population constituting CD44^-^ cells, a deviation from the original study and the Registered Report. We then used quantitative real-time-polymerase chain reaction (qRT-PCR) to assess let-7b and miR-34a expression in CD44^+^ and CD44^-^ LAPC4 cell populations. We found that let-7b was underexpressed in CD44^+^ cells, being expressed at 0.20% of the level in the CD44^-^ cells, while miR-34a was elevated in level in CD44^+^ cells, being expressed at 202% of the level in the CD44^-^ cells ([Figure 1](#fig1){ref-type="fig"}). The original study reported both let-7b and miR-34a were underexpressed in CD44^+^ LAPC4 cells at 30% and 3.4% of the level in CD44^-^ cells, respectively ([@bib19]). The decision to define the CD44^+^ population as a smaller fraction of the total population than the original study (1% vs 10%) was done to minimize any potential masking of reduced microRNA expression by not including what would have been a relatively large population (90%) of cells that were not positive for CD44 based on controls. Importantly, we observed let-7b levels were reduced in CD44^+^ cells, relative to CD44^-^ cells, as expected and similar to the original study despite the difference in how populations were defined. However, this creates a potential confound, particularly in the CD44^-^ population as defined for this replication, that could contain cells that were positive for CD44 complicating the comparison of microRNA levels between these populations. To summarize, for this experiment we found results that were in the same direction as the original study for let-7b expression, but not for miR-34a expression.

Effect of miR-34a expression on tumor growth {#s2-2}
--------------------------------------------

LAPC4 tumor cells were used to replicate an experiment that tested the effect of miR-34a on tumor growth. This experiment is similar to what was reported in Supplemental Figure 5C of [@bib19] and described in Protocol 4 in the Registered Report ([@bib17]). Untransduced LAPC4 cells, which were not included in the original study, were added as an additional control. LAPC4 cells purified from xenograft tumors were transduced with the same lentiviral vectors used in the original study to create stable miR-34a producing cells, which expressed higher levels of miR-34a compared to untransduced or negative control transduced LAPC4 cells ([Figure 2A](#fig2){ref-type="fig"}). Following infection, cells were injected into male NOD/SCID mice and monitored for tumor development. Tumor incidence was 100% for all groups, similar to the original study, with the three groups having the same median latency time ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). After 100 days, tumors were excised and weighed. Tumors from negative control transduced cells grew to an average of 0.51 grams \[n = 7, *SD* = 0.28\] ([Figure 2B](#fig2){ref-type="fig"}) similar to the weight reported for this group in the original study \[0.54 grams, *SD* = 0.32, n = 6\], which was the planned stopping rule in the Registered Report. The original study observed this at 69 days post injection. The original study reported expression of miR-34a inhibited tumor regeneration of LAPC4 cells \[0.15 grams, *SD* = 0.09, n = 6\] ([@bib19]), while in this replication attempt, we observed LAPC4 cells engineered to express miR-34a resulted in similar tumor weights \[0.55 grams, *SD* = 0.17, n = 7\] as the untransduced or negative control transduced LAPC4 cells ([Figure 2B](#fig2){ref-type="fig"}). The planned comparisons of the miR-34a group to the negative control group (*t*(18) = 0.432, *p*=0.671) or the untransduced group (*t*(18) = 0.414, *p*=0.684) were not statistically significant. In addition to collecting tumor weights, we monitored tumor volume, determined by caliper, during the course of the study and observed similar growth profiles for the three groups ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). To summarize, we found results that were not in the same direction as the original study and not statistically significant.

![Effect of miR-34a expression on tumor growth and CD44 expression in LAPC4 tumors.\
Purified LAPC4 cells were transduced to express miR-34a before injection into male NOD/SCID mice. (**A**) Relative expression levels of miR-34a (normalized to miR-103) was determined by qRT-PCR for LAPC4 cells left untransduced (UT), or transduced with lentivirus encoding scramble negative control (miR-NC) or pre-miR-34 (miR-34a). For each condition, expression level was made relative to UT which were assigned a value of 1. Means reported from one biological repeat. (**B**) At the end of the experiment (100 days post injection), primary tumors were excised and weighed. Dot plot with means reported as crossbars and error bars represent *SD*. Number of primary tumors per group (n = 7). One-way ANOVA on all three groups: *F*(2,18) = 0.119, *p*=0.888. Planned contrast between miR-34a and miR-NC: Fisher's LSD test, *t*(18) = 0.432, *p*=0.671. Planned contrast between miR-34a and UT: Fisher's LSD test, *t*(18) = 0.414, p=0.684. (**C**) Following primary tumor detection, caliper measurements were taken three times a week and used to calculate tumor volume. Line graph of tumor volume (y-axis is natural log scale) with means reported and error bars representing *SD*. Number of mice monitored per group (n = 7). One-way ANOVA on area under the curve (natural log-transformed) for all three groups: *F*(2,18) = 0.916, *p*=0.418. Planned contrast between miR-34a and miR-NC: Fisher's LSD test, *t*(18) = 0.680, *p*=0.505, Cohen's *d* = −0.36, 95% CI \[−1.41, 0.70\]. Planned contrast between miR-34a and UT: Fisher's LSD test, *t*(18) = 0.673, *p*=0.509, Cohen's *d* = 0.36, 95% CI \[−0.70, 1.41\]. (**D**) Relative expression levels of miR-34a (normalized to miR-103) was determined by qRT-PCR from excised tumors. For each condition, expression level was made relative to UT. Dot plot with means reported as crossbars and error bars represent *SD*. Of note, no signal was detected in any of the tumors derived from miR-34a transduced LAPC4 cells. (**E**) Relative expression levels of CD44 (normalized to ß-actin) was determined by Western blot from excised tumors. For each condition, expression level are presented relative to UT. Box and whisker plot with median represented as the line through the box and whiskers representing values within 1.5 IQR of the first and third quartile. Individual data points represented as dots. Additional details for this experiment can be found at [https://osf.io/n9vrz/](https://osf.io/n9vrz/.).](elife-43511-fig2){#fig2}

The excised tumors were further assessed for miR-34a and CD44 expression. We measured miR-34a expression by qRT-PCR. This experiment was described in Protocol 6 in the Registered Report ([@bib17]) and is conceptually similar to what was reported in Supplemental Figure 4A,B of [@bib19]. The original study reported no, or marginal (\~3X), increases in miR-34a expression in the residual tumors formed from prostate cancer cells, specifically LAPC4, LAPC9, and DU145, transiently transfected with miR-34a oligo compared to vector control ([@bib19]). An increase (\~3X over control) in miR-34a expression was also reported for tumors derived from DU145 cells transduced with lentiviral vectors to express miR-34a ([@bib19]). In this replication attempt, we detected miR-34a expression in tumors derived from untransduced or negative control transduced LAPC4 cells; however, unexpectedly we were unable to detect miR-34a in the tumors derived from miR-34a transduced LAPC4 cells ([Figure 2D](#fig2){ref-type="fig"}). Although miR-34a was not detectable in the tumors derived from miR-34a transduced LAPC4 cells, we were able to detect the copepod green fluorescent protein (copGFP) marker, which was under control of the elongation factor-1 (EF-1) alpha promoter. This suggests that the pre-miR-34a that successfully expressed mature miR-34a in LAPC4 cells *in vitro* ([Figure 2A](#fig2){ref-type="fig"}) was silenced *in vivo* ([Figure 2D](#fig2){ref-type="fig"}). This could have occurred through promoter hypermethylation or chromatin remodeling of the locus where the synthetic construct was expressed. Indeed, tumor suppressor microRNAs have been reported to be downregulated, or completely deleted, in a variety of cancers ([@bib13]; [@bib27]). Additionally, the cytomegalovirus (CMV) promoter, which controlled pre-miR-34a expression, has been reported to become silent in many animal studies within a few weeks after gene transfer ([@bib22]), which could be another mechanism responsible for this phenotype. Importantly, though, this observation does not necessarily imply miR-34a does not suppress tumor growth or progression in this experimental model since miR-34a overexpression was not confirmed *in vivo*. The different source of the LAPC4 cells between the original study and this replication attempt might have contributed to differences in miR-34a expression. It is also possible that silencing of miR-34a could have imparted a benefit at an early initiation step after cells were implanted in the mice and been maintained during tumor growth.

We also measured CD44 expression by Western blot in the excised tumors. This experiment was described in Protocol 5 in the Registered Report ([@bib17]) and is conceptually similar to what was reported in Figure 4A of [@bib19], which used DU145 cells transduced with a retroviral vector encoding miR-34a. The original study reported CD44 expression was inversely correlated with miR-34a expression in the tumors formed from the transduced DU145 cells ([@bib19]). In this replication attempt, we found CD44 expression in tumors derived from miR-34a transduced LAPC4 cells was similar to the expression in tumors derived from untransduced or negative control transduced LAPC4 cells ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). Interpretation of these results need to take into consideration the absence of miR-34a expression that was observed in the tumors from miR-34a transduced LAPC4 cells.

Evaluation of putative miR-34a binding sites in the 3'UTR of CD44 {#s2-3}
-----------------------------------------------------------------

We independently replicated an experiment to test if miR-34a regulates *CD44* expression through two putative miR-34a binding sites in the 3'UTR of *CD44*. DU145 cells were co-transfected with miR-34a oligos, or control oligos, and the same luciferase reporter plasmid used in the original study that contained a fragment of the 3'UTR of *CD44* with both putative miR-34a binding sites that were either left intact (wild-type) or mutated. This is similar to what was reported in Figure 4D of [@bib19] and described in Protocol 7 in the Registered Report ([@bib17]). While the original study tested each binding site individually as well as together as a double mutant, this replication attempt focused on the double mutant. We found DU145 cells transfected with the luciferase reporter, with wild-type binding sites, and miR-34a oligos were similar (mean relative expression = 0.99) to cells co-transfected with control oligos (mean relative expression = 1.00), which was not statistically significant (one-sample Wilcoxon signed-rank test: *z* = 0.517, uncorrected *p*=0.632; (Bonferroni corrected *p*\>0.99) ([Figure 3A](#fig3){ref-type="fig"}). Results were similar when DU145 cells were transfected with the luciferase reporter containing mutations in both binding sites (miR-34a: mean relative expression = 1.19; control: mean relative expression = 1.00). The original study reported cells co-transfected with the wild-type luciferase reporter and miR-34a oligos resulted in a decreased luciferase signal (mean relative expression = 0.67) compared to cells co-transfected with control oligos (mean relative expression = 1.00), which was partially abrogated with the double mutant luciferase reporter (miR-34a: mean relative expression = 0.78; control: mean relative expression = 1.00) ([@bib19]). In addition to analyzing the data like the original study, where luciferase values from cells transfected with miR-34a oligos were reported normalized to control oligo values for each biological repeat and each luciferase reporter, we also analyzed the data using the raw luciferase values. While we did not observe a difference between miR-34a and control oligos for each luciferase reporter, in agreement with the results of the prior analysis approach, we found the luciferase values from the double mutant luciferase reporter was on average lower than the wild-type luciferase reporter values ([Figure 3B](#fig3){ref-type="fig"}). Importantly, interpretation of results from experiments that overexpress microRNAs should take into account artificial repression that could occur from non-physiological stoichiometry of the overexpressed microRNA as well as relieved repression of natural targets of other microRNAs ([@bib31]). To summarize, we found results that were not consistent in direction with the original study and not statistically significant.

![Luciferase assays to assess putative miR-34a binding sites in the 3'UTR of CD44.\
DU145 cells were transfected with either a luciferase reporter with a fragment of the 3'UTR of *CD44* with both putative miR-34a binding sites left intact (wt) or mutated (M1M2). Cells were also co-transfected with miR-34a oligos (34a) or control oligos (NC). (**A**) Luciferase (Luc) activity was normalized to the NC condition for both luciferase reporters for each biological repeat such that NC conditions were assigned a value of 1. Means reported and error bars represent s.e.m. from 16 independent biological repeats. Wilcoxon-Mann-Whitney test comparing Luc values from wt +34 a vs M1M2 + 34 a; *U* = 104, uncorrected *p*=0.381, Bonferroni adjusted significance threshold = 0.0167; (Bonferroni corrected *p*\>0.99). One-sample Wilcoxon signed-rank test comparing Luc values from wt +34 a to a constant of 1 (wt +NC); *z* = 0.517, uncorrected *p*=0.632; (Bonferroni corrected *p*\>0.99). One-sample Wilcoxon signed-rank comparing Luc values from M1M2 + 34 a to a constant of 1 (M1M2 + NC); *z* = 0.310, uncorrected *p*=0.782; (Bonferroni corrected *p*\>0.99). (**B**) This is the same data as in part (**A**), but Luc activity was not normalized. Luc values are presented relative to wt +NC. Box and whisker plot (y-axis is log~10~ scale) with median represented as the line through the box and whiskers representing values within 1.5 IQR of the first and third quartile. Kruskal-Wallis test on all four groups: H(3) = 11.1, *p*=0.011. Wilcoxon-Mann-Whitney comparison between luciferase reporter (wt or M1M2): *U* = 266, uncorrected *p*=7.67×10^−4^, Bonferroni corrected *p*=1.53×10^−3^, Cliff's *d* = 0.48, 95% CI \[0.19, 0.69\]. Wilcoxon-Mann-Whitney comparison between oligo (NC or 34a): *U* = 497, uncorrected *p*=0.847, Bonferroni corrected *p*\>0.99, Cliff's *d* = 0.03, 95% CI \[−0.25, 0.30\]. Wilcoxon-Mann-Whitney comparison between wt +NC and wt +M1M2: *U* = 119, uncorrected *p*=0.752, Bonferroni corrected *p*\>0.99, Cliff's *d* = 0.07, 95% CI \[−0.32, 0.44\]. Additional details for this experiment can be found at [https://osf.io/vzb82/](https://osf.io/vzb82/.).](elife-43511-fig3){#fig3}

![Meta-analyses of each effect.\
Effect size and 95% confidence interval are presented for [@bib19], this replication study (RP:CB), and a random effects meta-analysis of those two effects. Cohen's *d* and Glass' delta are standardized differences between the two indicated measurements with the calculated effects for the original study effects reported as positive values. Sample sizes used in [@bib19] and RP:CB are reported under the study name. (**A**) Tumor weights from LAPC4 cells transduced to express miR-34a or negative control (meta-analysis *p*=0.510). (**B**) Luciferase values from cells transfected with miR-34a and wild-type luciferase reporter (wt) compared to cells transfected with miR-34a and double mutant luciferase reporter (M1M2) (meta-analysis *p*=0.353). (**C**) Luciferase values from cells transfected with miR-34a and wt compared to a constant of 1 (miR-NC and wt) (meta-analysis *p*=0.416), and luciferase values from cells transfected with miR-34a and M1M2 compared to a constant of 1 (miR-NC and M1M2) (meta-analysis *p*=0.581). Additional details for these meta-analyses can be found at [https://osf.io/p9xn8/](https://osf.io/p9xn8/.).](elife-43511-fig4){#fig4}

Meta-analysis of original and replication effects {#s2-4}
-------------------------------------------------

We performed a meta-analysis using a random-effects model, where possible, to combine each of the effects described above as pre-specified in the confirmatory analysis plan ([@bib17]). To provide a standardized measure of the effect, a common effect size was calculated for each effect from the original and replication studies. Cohen's *d* is the standardized difference between two independent means using the pooled sample standard deviation. For a one-sample test, Cohen's *d* is the difference between the sample mean and the null value using the sample standard deviation. The effect size Glass' delta is a standardized difference between two means using the standard deviation of only the control group. Glass' delta was used when the variance between the two conditions were not equal, which occurred in the original study for some of the experiments. The estimate of the effect size of one study, as well as the associated uncertainty (i.e. confidence interval (CI)), compared to the effect size of the other study provides another approach to compare the original and replication results ([@bib7]; [@bib33]). Importantly, the width of the confidence interval for each study is a reflection of not only the confidence level (e.g. 95%), but also variability of the sample (e.g. *SD*) and sample size.

The comparison of tumor weights between tumors derived from miR-34a transduced LAPC4 cells compared to negative control, which were reported in [Figure 2B](#fig2){ref-type="fig"} of this study and Supplemental Figure 5C of [@bib19], resulted in effect sizes that were in opposite direction between the two studies and the effect size point estimate of each study was not within the 95% CI of the other study ([Figure 4A](#fig4){ref-type="fig"}). The meta-analysis of these two effects was not statistically significant (*p*=0.510).

There were three comparisons made with the luciferase reporter data, which were reported in [Figure 3A](#fig3){ref-type="fig"} of this study and Figure 4D of [@bib19]. A comparison of luciferase values from cells transfected with miR-34a oligos, normalized to control oligo values, was made between wild-type and double mutant luciferase reporters. The effect sizes from the original study and this replication attempt were in the same direction and the effect size point estimates of each study were within the 95% CI of the other study ([Figure 4B](#fig4){ref-type="fig"}). The 95% CI for both studies also crossed zero, which indicates the null hypothesis that there is no difference between the two luciferase reporters can not be rejected. This is in agreement with the meta-analysis that was not statistically significant (*p*=0.353). Additionally, the luciferase values from miR-34a oligos normalized to control oligo values were compared to a constant of 1, which represents the control oligo group for each of the luciferase reporters ([Figure 4C](#fig4){ref-type="fig"}). This is analogous to a one-sample *t* test. For the wild-type luciferase reporter, the original study and this replication attempt were in the same direction with the effect size of the replication within the 95% CI of the original study, but not vice versa. For the double mutant luciferase reporter, the effect sizes were in opposite directions between the two studies and the effect size point estimate of each study was not within the 95% CI of the other study. For both reporters, the 95% CI for both studies also crossed zero. We used the one-sample approach because of the way the original data were handled, where the control oligo for each biological repeat and each luciferase reporter were assigned values of 1 without an associated variance making an unpaired two-sample test inappropriate. This possibly explains why the original study reported a statistically significant effect between control and miR-34a for the wild-type luciferase reporter when using an unpaired test in contrast to the calculated 95% CI of the effect size for the original study presented in [Figure 4C](#fig4){ref-type="fig"} that crosses zero, which indicates the null hypothesis that there is no difference between miR-34a oligo transfected cells and the constant of 1 (i.e. control oligo) can not be rejected. This is in agreement with the meta-analyses that were not statistically significant (wild-type: *p*=0.416; double mutant: *p*=0.581). Additionally for these two comparisons, the large CI of the meta-analyses along with statistically significant Cochran's *Q* tests (wild-type: *p*=0.047; double mutant: *p*=0.021) suggest heterogeneity between the original and replication studies.

This direct replication provides an opportunity to understand the present evidence of these effects. Any known differences, including reagents and protocol differences, were identified prior to conducting the experimental work and described in the Registered Report ([@bib17]). However, this is limited to what was obtainable from the original paper and through communication with the original authors, which means there might be particular features of the original experimental protocol that could be critical, but unidentified. So while some aspects, such as cell line, mouse strain, antibodies, and plasmids were maintained others were changed in the execution of the replication, such as source of the LAPC4 cells and flow cytometry gating strategy. Furthermore, other aspects were unknown or not easily controlled for. These include variables such as cell line genetic drift ([@bib2]; [@bib9]; [@bib15]), subclonal drift in heterogeneous stable cells ([@bib29]), genetic heterogeneity of mouse inbred strains ([@bib4]), and the microbiome of recipient mice ([@bib23]). Whether these or other factors influence the outcomes of this study is open to hypothesizing and further investigation, which is facilitated by direct replications and transparent reporting.

Materials and methods {#s3}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\            Designation                                                Source or\                                                                                                         Identifiers                                                                                 Additional\
  (species) or\                                                                       reference                                                                                                                                                                                                      information
  resource                                                                                                                                                                                                                                                                                           
  ------------------------ ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Strain,\                 NOD/SCID                                                   Vital River                                                                                                        Strain code: 406; RRID:[IMSR_CRL:394](https://scicrunch.org/resolver/IMSR_CRL:394)          
  strain background\                                                                                                                                                                                                                                                                                 
  (*Mus*\                                                                                                                                                                                                                                                                                            
  *musculus*,\                                                                                                                                                                                                                                                                                       
  NOD/SCID, male)                                                                                                                                                                                                                                                                                    

  Cell line\               LAPC4                                                      doi:[10.1038/nm0497-402](https://www.nature.com/articles/nm0497-402)                                               RRID:[CVCL_4744](https://scicrunch.org/resolver/CVCL_4744)                                  shared by Dr. Dean G Tang, MD Anderson Cancer Center and Dr. Charles L Sawyers, Memorial Sloan Kettering Cancer Center
  (*Homo sapiens*, male)                                                                                                                                                                                                                                                                             

  Cell line\               DU145                                                      ATCC                                                                                                               cat\#:HTB-81; RRID:[CVCL_0105](https://scicrunch.org/resolver/CVCL_0105)                    
  (*H. sapiens*, male)                                                                                                                                                                                                                                                                               

  Cell line\               HT-1080                                                    ATCC                                                                                                               cat\#:CCL-121; RRID:[CVCL_0317](https://scicrunch.org/resolver/CVCL_0317)                   
  (*H. sapiens*, male)                                                                                                                                                                                                                                                                               

  Cell line\               HEK293T                                                    ATCC                                                                                                               cat\#:CRL-3216; RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)                  
  (*H. sapiens*)                                                                                                                                                                                                                                                                                     

  Chemical\                testosterone propionate                                    Aladdin                                                                                                            CAS:57-85-2                                                                                 lot\# L1401028
  compound, drug                                                                                                                                                                                                                                                                                     

  Other                    Matrigel                                                   BD Biosciences                                                                                                     cat\#:354248                                                                                

  Antibody                 FITC-conjugated monoclonal anti-CD44                       BD Biosciences                                                                                                     cat\#:555478; clone:G44-26; RRID:[AB_395870](https://scicrunch.org/resolver/AB_395870)      1:13 dilution

  Antibody                 FITC-conjugated monoclonal mouse IgG2b,κ isotype control   BD Biosciences                                                                                                     cat\#:555742; clone:27--35; RRID:[AB_396085](https://scicrunch.org/resolver/AB_396085)      1:13 dilution

  Antibody                 rabbit anti-CD44                                           AbCam                                                                                                              cat\#:ab51037; clone:EPR1013Y; RRID:[AB_868936](https://scicrunch.org/resolver/AB_868936)   1:1000 dilution

  Antibody                 mouse anti-ß-actin                                         Cell Signaling Technology                                                                                          cat\#:3700; clone:8H10D10; RRID:[AB_2242334](https://scicrunch.org/resolver/AB_2242334)     1:1000 dilution

  Antibody                 HRP-conjugated goat anti-rabbit                            Cell Signaling Technology                                                                                          cat\#:7074; RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)                    1:2000 dilution

  Antibody                 HRP-conjugated horse anti-mouse                            Cell Signaling Technology                                                                                          cat\#:7076; RRID:[AB_330924](https://scicrunch.org/resolver/AB_330924)                      1:5000 dilution

  Commercial\              MACS Lineage Cell Depletion Kit                            Miltenyi Biotech                                                                                                   cat\#:130-090-858                                                                           
  assay, kit                                                                                                                                                                                                                                                                                         

  Recombinant\             psPAX2                                                     Crown Biosciences, Inc                                                                                             RRID:[Addgene_12260](https://scicrunch.org/resolver/Addgene_12260)                          
  DNA reagent                                                                                                                                                                                                                                                                                        

  Recombinant\             pMD2.G                                                     Crown Biosciences, Inc                                                                                             RRID:[Addgene_12259](https://scicrunch.org/resolver/Addgene_12259)                          
  DNA reagent                                                                                                                                                                                                                                                                                        

  Recombinant\             pMDLg/pRRE                                                 Wuhan Miaoling Bioscience and\                                                                                     cat\# P0685; RRID:[Addgene_12251](https://scicrunch.org/resolver/Addgene_12251)             
  DNA reagent                                                                         Technology Co.                                                                                                                                                                                                 

  Recombinant\             pre-mir-34a                                                System Biosciences                                                                                                 cat\# PMIRH34aPA-1                                                                          
  DNA reagent                                                                                                                                                                                                                                                                                        

  Recombinant\             scramble non-targeting pre-miRNA                           System Biosciences                                                                                                 cat\# PMIRH000PA-1                                                                          
  DNA reagent                                                                                                                                                                                                                                                                                        

  Recombinant\             pMIR-CD44-3\'UTR                                           doi:[10.1038/nm.2284](https://www.nature.com/articles/nm.2284)                                                                                                                                                 shared by Dr. Dean G Tang, MD Anderson Cancer Center
  DNA reagent                                                                                                                                                                                                                                                                                        

  Recombinant\             pMIR-CD44-M1M2-3\'UTR                                      doi:[10.1038/nm.2284](https://www.nature.com/articles/nm.2284)                                                                                                                                                 shared by Dr. Dean G Tang, MD Anderson Cancer Center
  DNA reagent                                                                                                                                                                                                                                                                                        

  Recombinant\             phRL-CMV                                                   doi:[10.1038/nm.2284](https://www.nature.com/articles/nm.2284)                                                                                                                                                 shared by Dr. Dean G Tang, MD Anderson Cancer Center
  DNA reagent                                                                                                                                                                                                                                                                                        

  Sequence-based\          copGFP                                                     doi:[10.1111/j.1745-7270.2008.00448.x](https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1745-7270.2008.00448.x)                                                                                               Forward: 5\'-AGGACAGCGTGATCTTCACC-3\'; Reverse: 5\'-CTTGAAGTGCATGTGGCTGT-3\'
  reagent                                                                                                                                                                                                                                                                                            

  Sequence-based\          miR-34a miRNA TaqMan assay kit                             Applied Biosystems                                                                                                 assayID:000426                                                                              
  reagent                                                                                                                                                                                                                                                                                            

  Sequence-based\          has-let-7b miRNA TaqMan assay kit                          Applied Biosystems                                                                                                 assayID:000378                                                                              
  reagent                                                                                                                                                                                                                                                                                            

  Sequence-based\          miR-103 miRNA TaqMan assay kit                             Applied Biosystems                                                                                                 assayID:000439                                                                              
  reagent                                                                                                                                                                                                                                                                                            

  Sequence-based\          has-miR-34a-5p                                             Thermo Fisher Scientific                                                                                           assayID:MC11030                                                                             
  reagent                                                                                                                                                                                                                                                                                            

  Sequence-based\          negative control \#1                                       Thermo Fisher Scientific                                                                                           cat\#:4464058                                                                               
  reagent                                                                                                                                                                                                                                                                                            

  Software,\               GeneMapper                                                 Applied Biosystems                                                                                                 RRID:[SCR_014290](https://scicrunch.org/resolver/SCR_014290)                                version 4.0
  algorithm                                                                                                                                                                                                                                                                                          

  Software,\               Studylog Systems                                           Studylog                                                                                                           RRID:[SCR_016682](https://scicrunch.org/resolver/SCR_016682)                                version 3.1.399.19
  algorithm                                                                                                                                                                                                                                                                                          

  Software, algorithm      FACSDiva                                                   BD Biosciences                                                                                                     RRID:[SCR_001456](https://scicrunch.org/resolver/SCR_001456)                                version 6.1.3

  Software, algorithm      MxPro QPCR                                                 Stratagene                                                                                                         RRID:[SCR_016375](https://scicrunch.org/resolver/SCR_016375)                                version 4.1

  Software, algorithm      ImageJ                                                     doi:[10.1038/nmeth.2089](https://www.nature.com/articles/nmeth.2089)                                               RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)                                version 1.50a

  Software, algorithm      EnVision                                                   Perkin Elmer                                                                                                       RRID:[SCR_016681](https://scicrunch.org/resolver/SCR_016681)                                version 1.12

  Software, algorithm      R Project for statistical computing                        <https://www.r-project.org>                                                                                        RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)                                version 3.5.1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As described in the Registered Report ([@bib17]), we attempted a replication of the experiments reported in Figures 1B, 4A and D and Supplemental Figures 4A,B and 5C of [@bib19]. A detailed description of all protocols can be found in the Registered Report ([@bib17]) and are described below with additional information not listed in the Registered Report, but needed during experimentation.

Cell culture {#s3-1}
------------

LAPC4 (RRID:[CVCL_4744](https://scicrunch.org/resolver/CVCL_4744)) (shared by Dr. Dean G. Tang, MD Anderson Cancer Center and Dr. Charles L. Sawyers, Memorial Sloan Kettering Cancer Center), DU145 cells (ATCC, cat\# HTB-81, RRID:[CVCL_0105](https://scicrunch.org/resolver/CVCL_0105)), HT-1080 (ATCC, cat\# CCL-121, RRID:[CVCL_0317](https://scicrunch.org/resolver/CVCL_0317)), and HEK293T cells (ATCC, cat\# CRL-3216, RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)) were maintained in growth medium as described in the Registered Report ([@bib17]) with IMDM (Gibco, cat\# 21056--023) for LAPC4 cells sourced differently than listed. LAPC4 cells from Sawyers lab, which were used in the experiments reported here, were maintained for five passages in culture prior to mouse injection. Quality control data for cell lines are available at <https://osf.io/6u42f/.> This includes results confirming the cell lines were free of mycoplasma contamination as well as STR DNA profiling of the cell lines. STR profile performed by (DDC Medical, Fairfield, Ohio) or the following methods: DNA from cells were extracted with a genomic DNA extraction kit (Axygen Scientific, Inc, Union City, California), amplified using the 20 - STR amplification approach, then detected and analyzed for STR loci and the sex determination gene Amelogenin using a 3730XL DNA analyzer (Applied Biosystems, Inc, Foster City, California) and GeneMapper software (RRID:[SCR_014290](https://scicrunch.org/resolver/SCR_014290)), version 4.0. Cells were confirmed to be the indicated cell lines when queried against STR profile databases (DSMZ and Cellosaurus ([@bib1])).

Animals {#s3-2}
-------

All animal procedures were approved by the Crown Biosciences, Inc animal use committee (Animal Use Protocol\# AN-1507-007-108) and were in accordance with the Crown Biosciences policies on the care, welfare, and treatment of laboratory animals. Randomization and blinding occurred during lentiviral infection of LAPC4 cells and tumor implantation experiments. Randomization was performed based on 'matched distribution' randomization method using the multi-task method (Studylog Systems software; RRID:[SCR_016682](https://scicrunch.org/resolver/SCR_016682), version 3.1.399.19) on Day 0.

Six to seven week old male NOD/SCID mice (Vital River, Strain code: 406, RRID:[IMSR_CRL:394](https://scicrunch.org/resolver/IMSR_CRL:394)) were housed in sterile conditions under standard temperature, humidity, and timed lighting conditions with 12 hr light/dark cycles, and were provided with sterile rodent chow and water *ad libitum*. Animals were monitored daily and body weight and tumor volume was recorded weekly after injection.

Xenograft tumor maintenance {#s3-3}
---------------------------

After one week of acclimation, male NOD/SCID mice were implanted with a testosterone pellet as described in the Registered Report ([@bib17]). Pellets were prepared as described previously ([@bib25]) with testosterone propionate (CAS: 57-85-2; Aladdin, Shanghai, China; lot\# L1401028) and a 2 mm by 4 mm die set (International Crystal Laboratories, Garfield, New Jersey). Immediately after testosterone pellet implantation, mice were inoculated subcutaneously in the flank with 2 × 10^6^ LAPC4 cells suspended in 30 µl IMDM supplemented with 10% FBS and 30 µl high concentration Matrigel (BD Biosciences, cat\# 354248).

Purification of LAPC4 cells from xenograft tumors {#s3-4}
-------------------------------------------------

Tumors were excised when they reached 1 to 1.5 cm^3^ (122--125 days after injection), weighed, and dissociated for purification of LAPC4 cells as described in the Registered Report ([@bib17]). Tumor weight and cell viability counts before and after Histopaque-1077 gradient and depletion of lineage-positive (i.e. mouse) cells using the MACS Lineage Cell Depletion Kit (Miltenyi Biotech, cat\# 130-090-858) are available at <https://osf.io/4jbhf/.> Purified LAPC4 cells were then used for experiments.

Lentiviral infection of LAPC4 cells and tumor implantation {#s3-5}
----------------------------------------------------------

Lentiviral particles were generated in HEK293T cells with psPAX2 (Crown Biosciences Inc, RRID:[Addgene_12260](https://scicrunch.org/resolver/Addgene_12260)), pMD2.G (Crown Biosciences Inc, RRID:[Addgene_12259](https://scicrunch.org/resolver/Addgene_12259)), and pMDLg/pRRE (Wuhan Miaoling Bioscience and Technology Co., cat\# P0685, RRID:[Addgene_12251](https://scicrunch.org/resolver/Addgene_12251)) plasmids and viral titer was determined using HT1080 cells as described in the Registered Report ([@bib17]). Plasmids were purified using an endo-free maxiprep kit (Qiagen, cat\# 12362) and identity of vectors were confirmed by sequencing and agarose gel electrophoresis (<https://osf.io/rk42q/>). Purified LAPC4 cells (pooled from three tumors) were transduced with lentiviral particles engineered to express pre-mir-34a (System Biosciences, cat\# PMIRH34aPA-1) or scramble non-targeting pre-miRNA (System Biosciences, cat\# PMIRH000PA-1) at an MOI of 10. The lentiviral vectors use the CMV promoter to drive pre-miRNA expression and the copGFP marker under the control of the EF-1 alpha promoter. During infection LAPC4 cells were kept in a single cell suspension in ultra-low attachment flasks in growth medium at 37°C in a humidified atmosphere at 5% CO~2~. 48 hr post-infection male NOD/SCID mice were inoculated subcutaneously in the flank with 1 × 10^4^ LAPC4 cells suspended in 20 µl IMDM supplemented with 15% FBS and 20 µl high concentration Matrigel. Mice were randomized by body weight at time of injection and was consistent with even distribution across all groups (one-way ANOVA: *F*(2,18) = 0.0003, *p*=0.9997). Infected LAPC4 cells were confirmed to be at least 90% transduction efficiency (determined by GFP) at time of injection (representative microscopy images available at <https://osf.io/hrbd8/>) with aliquots of cells saved for qPCR analysis. Mice were monitored until the negative control transduced group reached an average estimated tumor weight (based on tumor volume calculations) of 0.54 grams. Mice were euthanized and primary tumors were weighed (scale: Mettler Toledo, Columbus, Ohio), with pictures of the tumors taken with a ruler for scale (available at <https://osf.io/k28ab/>). Tumors were divided into two pieces: one for protein extraction (snap frozen) and one for RNA extraction (immerged in RNAlater (Invitrogen, cat\# AM7021) overnight and then frozen).

Fluorescence-activated cell sorting {#s3-6}
-----------------------------------

2.1 × 10^6^ purified LAPC4 cells (pooled from three tumors) were resuspended in 100 µl cold staining buffer and separated into two tubes. 20 µl FcR blocking reagent and 10 µl of FITC-conjugated monoclonal anti-CD44 (BD Biosciences, cat\# 555478, clone G44-26, RRID:[AB_395870](https://scicrunch.org/resolver/AB_395870)) or FITC-conjugated monoclonal mouse IgG2~b~, κ isotype control (BD Biosciences, cat\# 555742, clone 27--35, RRID:[AB_396085](https://scicrunch.org/resolver/AB_396085)) was added and incubated at 4 ˚C in the dark for 15 min. Flow cytometry analysis was performed on a FACSAria II (BD Biosciences) and analyzed with FACSDiva software (BD Biosciences, RRID:[SCR_001456](https://scicrunch.org/resolver/SCR_001456)), version 6.1.3. Gating strategy is depicted in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}. An initial attempt was performed, which revealed few purified LAPC4 cells were CD44 positive relative to isotype control. As such, the gating strategy differed to include only the top 1% of the population, instead of the top 10%, with the remaining population constituting CD44^-^ cells. Human peripheral blood mononuclear cells (PBMC) were also tested to confirm specificity of the antibodies and staining procedure ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

Quantitative PCR {#s3-7}
----------------

Small RNA-containing total RNA was isolated from FACS sorted LAPC4 cells using the *mir*Vana miRNA Isolation Kit (Invitrogen, cat\# AM1561) or infected purified LAPC4 cells or tumors using the *mir*Vana PARIS RNA Isolation Kit (Invitrogen, cat\# AM1556) according to manufacturer's instructions. miRNA was reverse transcribed to cDNA using TaqMan MicroRNa Reverse Transcription Kit (Applied Biosystems, cat\# 4366596) according to manufacturer's instructions. DNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific, cat\# ND-2000). qPCR was performed in technical triplicate using an MX3005P Real-time PCR System (Stratagene) with assays specific for each miRNA of interest as outlined in the Registered Report ([@bib17]). To detect copGFP expression, the following primers were used (Forward: 5'-AGGACAGCGTGATCTTCACC-3'; Reverse: 5'-CTTGAAGTGCATGTGGCTGT-3') ([@bib36]). PCR reactions were performed in technical triplicate with the following cycling conditions \[1 cycle 95°C for 10 min -- 40 cycles 95°C for 15 s, 60°C for 60 s\] using an Mx3005P Real-time PCR System (Stratagene) and MxPro QPCR software (RRID:[SCR_016375](https://scicrunch.org/resolver/SCR_016375)), version 4.1. Negative controls containing no cDNA template were included. Relative expression levels were determined using the ∆∆Ct method.

Western blots {#s3-8}
-------------

Cell lysate was generated from tumor samples as described in the Registered Report ([@bib17]). Membranes were loaded with 40 µg of total protein and probed with: rabbit anti-CD44 (AbCam, cat\# ab51037, clone EPR1013Y, RRID:[AB_868936](https://scicrunch.org/resolver/AB_868936)), 1:1000 dilution; mouse anti-ß-actin (Cell Signaling Technology, cat\# 3700, clone 8H10D10, RRID:[AB_2242334](https://scicrunch.org/resolver/AB_2242334)), 1:1000 dilution and the appropriate secondary antibody: HRP-conjugated goat anti-rabbit (Cell Signaling Technology, cat\# 7074, RRID:[AB_2099233](https://scicrunch.org/resolver/AB_2099233)), 1:2000 dilution; HRP-conjugated horse anti-mouse (Cell Signaling Technology, cat\# 7076, RRID:[AB_330924](https://scicrunch.org/resolver/AB_330924)), 1:5000 dilution. Membranes were washed with TBST and incubated with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, cat\# 34080) according to the manufacturer's instructions. Scanned Western blots were quantified using ImageJ software (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)), version 1.50a.

Luciferase assay {#s3-9}
----------------

3 × 10^4^ DU145 cells in 500 µl growth medium were plated in 24 well plates and incubated overnight at 37°C in a humidified atmosphere at 5% CO~2~. The following day, cells were checked to make sure they were 70--90% confluent at the time of transfection and new growth medium not containing penicillin-streptomycin was added. Cells were transfected with 50 µl transfection complex such that each well would contain 1 µg luciferase reporter (pMIR-CD44-3'UTR or pMIR-CD44-M1M2-3'UTR (shared by Dr. Dean G. Tang, MD Anderson Cancer Center)), 1 ng phRL-CMV (shared by Dr. Dean G. Tang, MD Anderson Cancer Center), and 24 pmoles *mir*Vana miRNA mimics (has-miR-34a-5p (Thermo Fisher Scientific, Assay ID\# MC11030) or Negative Control \#1 (Thermo Fisher Scientific, cat\# 4464058)). Plasmids were purified using an endo-free maxiprep kit and identity of vectors were confirmed by sequencing and agarose gel electrophoresis (<https://osf.io/rk42q/>). 6 hr after transfection cells were replaced with fresh growth medium to increase cell viability as determined necessary during pilot assays. Cells were incubated at 37°C in a humidified atmosphere at 5% CO~2~. 48 hr later the luciferase and renilla signals were determined using the dual luciferase assay (Promega, cat\# E1960), EnVision 2104 Multilabel Plate Reader (Perkin Elmer), and EnVision software (Perkin Elmer; RRID:[SCR_016681](https://scicrunch.org/resolver/SCR_016681)), version 1.12, according to manufacturer's instructions. Additional method details and raw data are available at <https://osf.io/vzb82/.>

Statistical analysis {#s3-10}
--------------------

Statistical analysis was performed with R software (RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)), version 3.5.1 ([@bib6]). All data, csv files, and analysis scripts are available on the OSF (<https://osf.io/gb7sr/>). Confirmatory statistical analysis was pre-registered (<https://osf.io/jhtae/>) before the experimental work began as outlined in the Registered Report ([@bib17]). Data were checked to ensure assumptions of statistical tests were met and in the case of the tumor volume data were natural log transformed to achieve a normal distribution. The exploratory survival analysis was analyzed with a COX proportional hazard (CPH) model because ties, which were prevalent in the data, were better handled with CPH than a log-rank (Mantel-Cox) test. When described in the results, the Bonferroni correction, to account for multiple testings, was applied to the alpha error or the *p*-value. The Bonferroni corrected value was determined by divided the uncorrected value (0.05) by the number of tests performed. The asymmetric confidence intervals for the Cliff's *d* estimates were determined using the normal deviate corresponding to the (1 - alpha/2)^th^ percentile of the normal distribution ([@bib5]). A meta-analysis of a common original and replication effect size was performed with a random effects model and the *metafor* R package ([@bib35]) (<https://osf.io/p9xn8/>). The original study data pertaining to Figures 1B and 4D, and Supplemental Figure 5C were shared by the original authors or published in the original paper ([@bib19]). The summary data was published in the Registered Report ([@bib17]) and used in the power calculations to determine the sample size for this study.

Data availability {#s3-11}
-----------------

Additional detailed experimental notes, data, and analysis are available on OSF (RRID:[SCR_003238](https://scicrunch.org/resolver/SCR_003238)) (<https://osf.io/gb7sr/>; [@bib39]). This includes the R Markdown file (<https://osf.io/e89mt/>) that was used to compose this manuscript, which is a reproducible document linking the results in the article directly to the data and code that produced them ([@bib8]). Flow cytometry data for this study has also been deposited at Flow Repository (RRID:[SCR_013779](https://scicrunch.org/resolver/SCR_013779); [@bib30]), where it is directly accessible at <https://flowrepository.org/id/FR-FCM-ZYNB>.

Deviations from registered report {#s3-12}
---------------------------------

We obtained LAPC4 cells from the original authors, but as described above changed the source of these cells. We also modified the gating strategy when determining CD44^+^ and CD44^-^ populations as described above. Importantly, we included a control (PBMC) to confirm specificity of the antibodies and staining procedure ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Similarly, instead of obtaining enough purified CD44^+^ LAPC4 cells required using multiple tumors, which were pooled, instead of individual tumors as specified in the Registered Report. When we infected purified LAPC4 cells to express miR-34a we changed the source of the lentiviral packaging plasmids and modified the time from infection to injection from 24 hr to 48 hr. The reason is because we were unable to achieve high transduction efficiency (\>90% GFP positive) when the protocol was followed as described in the Registered Report. Importantly, the transduced LAPC4 cells successfully expressed miR-34a ([Figure 2A](#fig2){ref-type="fig"}). Additionally, because we were unable to detect miR-34a in the tumors derived from miR-34a transduced LAPC4 cells ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}) we analyzed the tumors to see if GFP was detectable, as an indicator of whether the tumors were derived from infected cells. Finally, we used ECL and film for the Western blots, instead of the Odyssey system outlined i the Registered Report. Additional materials and instrumentation not listed in the Registered Report, but needed during experimentation are also listed.

The Reproducibility Project: Cancer Biology would like to thank Dr. Can Liu and Dr. Dean G Tang (MD Anderson Cancer Center) for sharing critical information, data, and reagents, specifically plasmids and LAPC4 cells used in the original study. We want to thank Dr. Charles L Sawyers (Memorial Sloan Kettering Cancer Center) for sharing LAPC4 cells. We would also like to thank Courtney Soderberg (Center for Open Science) for assistance with statistical analyses, Young Kim (System Biosciences) for helpful discussions about how to detect copGFP, and the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type and Tissue Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).

Additional information {#s4}
======================

Crown Biosciences Inc is a Science Exchange associated lab.

Crown Biosciences Inc is a Science Exchange associated lab.

Crown Biosciences Inc is a Science Exchange associated lab.

Crown Biosciences Inc is a Science Exchange associated lab.

EI, RT, NP: Employed by and hold shares in Science Exchange Inc.

Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

Acquisition of data, Analysis and interpretation of data, Drafting or revising the article.

Analysis and interpretation of data, Drafting or revising the article.

Analysis and interpretation of data, Drafting or revising the article.

Analysis and interpretation of data, Drafting or revising the article.

Animal experimentation: All animal procedures were approved by the Crown Biosciences, Inc. animal use committee (Animal Use Protocol\# AN-1507-007-108) and were in accordance with the Crown Biosciences policies on the care, welfare, and treatment of laboratory animals.

Additional files {#s5}
================
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###### The ARRIVE guidelines checklist.

Data availability {#s6}
=================

Additional detailed experimental notes, data, and analysis are available on OSF (RRID:SCR_003238) (<https://osf.io/gb7sr/>; Yan et al., 2018). This includes the R Markdown file (<https://osf.io/e89mt/>) that was used to compose this manuscript, which is a reproducible document linking the results in the article directly to the data and code that produced them (Hartgerink, 2017). Flow cytometry data for this study has also been deposited at Flow Repository (RRID:SCR_013779; Spidlen et al., 2012), where it is directly accessible at <https://flowrepository.org/id/FR-FCM-ZYNB>.

The following datasets were generated:

YanXTangBChenBShanY2018Study 28: Replication of Liu et al., 2011 (Nature Medicine)Open Science Framework10.17605/OSF.IO/GB7SR

YanXTangBChenB2018Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44FlowrepositoryFR-FCM-ZYNB

10.7554/eLife.43511.017
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Sean Morrison as the Senior Editor. Andrea Ventura (Reviewer \#1) and Julie Liu (Reviewer \#4) have agreed to reveal their names.

Summary:

Your manuscript is recommended for publication in *eLife* pending satisfactory revisions of several remaining points. Specifically:

1\) Could the replication authors confirm whether their departure from the original conditions used by Liu et al. was approved as part of the original registered protocol? Could the authors elaborate and discuss the path to making this decision and the potential confounds?

2\) The observation that in the miR-34 over-expression experiment, miR-34 over-expression is lost raises concerns, as described by reviewer \#2. The authors need to address this concern.

3\) Address as much as possible the minor points identified by Referees \#1 and \#3.

*Reviewer \#1:*

This manuscript by Yan and colleagues is part of the \"Reproducibility Project\" and was aimed at replicating key experiments from the paper: \"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44\".

The original paper provided experimental evidence showing that miR-34a expression is reduced in CD44+ cells compared to CD44- cells prostate cancer cells and that ectopic expression of miR-34a is sufficient to strongly repress tumor formation in a xenograft assay. Moreover, the authors provided data showing that miR-34a exerts this potent tumor repressive activity at least in part by targeting the cell adhesion molecule CD44.

In the replication study, the Yan et al. fail to replicate key portions of the original study. In particular, they fail to detect significant down-regulation of miR-34a in CD44-Hi LPCA4 cells, fail to observe tumor growth inhibition when LAPC4 cells transduced with a miR-34a expressing lentivirus were injected in immunocompromised mice, and fail to detect significant repression by ectopic miR-34a in luciferase reporter assays. These results call into question the central message of the original publication.

The manuscript is well written, the experiments are clearly illustrated and their results are generally consistent with the authors\' interpretation. The relevant scientific literature is appropriately cited and the statistical analysis performed to reject the various null hypothesis is, as far as I can tell, sound.

The authors have also to be commended for carefully listing potential explanations for the discrepancy between their results and those reported in the original manuscript.

In particular, the fact that the LAPC4 cell line initially obtained by Liu and colleagues failed to generate tumors and had to be replaced by LAPC4 from a different source is worrisome, given the high genetic drift of cancer cell lines.

Equally perplexing is the observation that expression of the miR-34a transgene appears silenced in tumors isolated from mice injected with LAPC4 cells transduced with the mIR-34a overexpressing. This may suggest that there is a strong selection against miR-34a in vivo, but it doesn\'t explain why the same effect was not observed by Liu and colleagues. It is important to point out that there is abundant experimental evidence that ectopic expression of miR-34a can result in cell cycle arrest and apoptosis, although the evidence that loss of endogenous miR-34a is sufficient to promote or accelerate tumorigenesis is less conclusive.

Overall, this is a strong manuscript that, in my opinion deserves publication.

Minor issues:

The authors seem to imply that reduced expression of the luciferase reporter carrying the 3\'UTR of CD44 with point mutations disrupting the miR-34a sites could be explained by the fact that the WT 3\'UTR contains a potential miR-141 binding site overlapping one of the two miR-34a site. Unless there is something I have missed, I find this explanation illogical. If the putative miR-141 site is also disrupted in the mutant 3\'UTR one would expect increased luciferase activity, not reduced (loss of repression by miR-141). The authors should either remove or clarify this sentence.

\"To summarize, we found results that were in the same direction as the original study and not statistically significant where predicted\". This sentence is unclear.

*Reviewer \#2:*

It appears that multiple conclusions drawn from the original manuscript by Liu et al., are not confirmed by this replication study. It is unfortunate that based on the flow analysis, the replication authors were forced to deviate from the original study\'s experimental protocol when choosing the cut-off for CD44 high or CD44 low. Two deviations were made. The first was to use a 1% cutoff rather than the prior manuscripts\' 10% cutoff. The second was to assign the other 99% of the population to a CD44 low status. The authors could argue that 10% of the replication study\'s CD44 low population (9%/99%) is in fact CD44 high. I understand the replication authors\' potential reason for doing this: that there wasn\'t a clear CD44 high versus CD44 low cutoff. However, it does represent a significant departure from the prior work. Could the replication authors confirm whether this departure was approved as part of the original registered protocol? Could the authors perhaps elaborate and discuss the path to making this decision and the potential confounds?

The second concern is the observation that in the miR-34 over-expression experiment, miR-34 over-expression is lost. One hand, one may conclude that miR-34 over-expression in this experiment did not reduce tumor growth, given the data in the figure. However, there is a hazard in this, since the replication authors have themselves shown that miR-34 expression is silenced. Such silencing typically occurs when the microRNA is indeed suppressive to cancer progression (the original authors\' conclusion). One could imagine that such silencing may have imparted a benefit at an early initiation step (tumor re-initiation) and been maintained. Thus, this experimental observation does not allow one to draw the conclusion that miR-34 *does not* suppress tumor growth or progression in this system, since miR-34 over-expression is not confirmed in vivo.

The luciferase reporter experiment clearly shows that exogenously transfected miR-34a does not repress the wildtype reporter signal.

*Reviewer \#3:*

As a part of \"Reproducibility Project: Cancer Biology, this manuscript aims to duplicate the results of a previous publication \"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by 41 directly repressing CD44\" (Liu et al., 2011). The authors generated different observations from those reported by the Tang group, using the same/similar reagents and protocols whenever possible. The original paper by Liu et al. claimed that miR-34a negatively regulate CD44 in prostate cancer stem cells, as they reported the downregulation of miR-34a in CD44 high LAPC4 prostate cancer cells (the putative stem cell population), the suppression of tumor development and Cd44 downregulation by miR-34a overexpression in xenograft models, and the miR-34a dependent regulation of Cd44 in luciferase assays. However, the replication study made different observations, including a 2-fold increase of miR-34a in CD44 high versus CD44 low LAPC4 prostate cancer cells, no effect on tumor growth or Cd44 expression by miR-34a overexpression in the xenograft model, and no miR-34a-dependent regulation on CD44.

This manuscript has raised questions about the reproducibility of the original report by Liu et al. This reviewer agrees with the authors that the selected experiments constitute the core discoveries reported by the original paper, and should be the focus of reproducibility effort. Of particular importance is the biological effects of miR-34 in prostate cancer development, and the miR-34a dependent regulation of CD44 in prostate cancer cells. The authors have carefully designed and executed their experiments, they included appropriate controls wherever possible, and obtained solid results based on the reported experimental conditions. It is clear to this reviewer that these authors cannot reproduce some of the most important results from the original report. This paper is suited for publication at *eLife* upon revision.

Major comments:

1\) The key issue encountered by the reproducibility study is the cell line of choice. The LAPC4 cell line acquired from the Tang group only exhibited a partial match with the standard LAPC4 profiles in the DSMZ and Cellosaurus database, and more importantly, failed to generate xenograft tumors in NOD/SCID mice. Hence the authors had to acquire cytologically and functionally validated LAPC4 cells from a different source to perform this reproducibility study. This reviewer is wondering if the authors have contacted the Tang group to acquire additional information about the LAPC4 cell lines they had problems with, and made a second request for LAPC4 from the Tang group. It is unclear if the failure to reproduce the original observations is largely due to the cell line difference, or if there exist other contributing factors.

2\) To validate the tumor suppressor functions of miR-34a, the authors generated LAPC4 cells that overexpress miR-34a by lentiviral transduction, but observed no effect on tumor development or CD44 expression in xenograft models. However, miR-34a expression is silenced in vivo specifically in LAPC4 cells transduced by mir-34a lentiviral vectors, but not in control transduced or non-transduced LAPC4 cells. This observation implies that miR-34a expression could have a tumor suppressor function, hence its expression is selected against in vivo (this is consistent with the tumor suppressor effects of miR-34a in overexpression studies in other models). Again, the cell line difference could contribute significantly to the different observations between the two studies. It would be nice to have the authors provide a more in-depth discussion about this discrepancy in results.

3\) The original study reported a direct regulation between miR-34a and CD44 3\'UTR, but the extent of regulation reflected in luciferase assays was rather modest. Luciferase assays have been widely used to validate a direct regulation of a target mRNA by a miRNA, yet in my opinion, these assays are not very reliable, particularly for miRNA targets that are modestly regulated. Often times, these assays rely on overexpression of both miRNAs and luciferase reporters with wildtype or mutated 3\'UTRs to determine the extent of their direct interactions in cell lines. In addition to the binding between miRNAs and the target 3\'UTR, the relative expression levels between miRNAs and reporter, which often deviates from physiological conditions, play an important role in the results of the assay. Hence, I suggest that the authors include such discussion in their revised manuscript.

Minor comments:

1\) It is not appropriate to claim that \"miR-34a was overexpressed in CD44+ cells, being expressed at 202% of the level in the CD44- 139 cells 140 (Figure 1)\". miR-34a is elevated in level in CD44+ cells, but not necessarily overexpressed. Please be precise when describing this observation.

*Reviewer \#4:*

I strongly oppose the publication of this \'reproducibility\' manuscript, for the following considerations.

First of all, the conclusion of the original paper that miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 (Liu et al., 2011) was based on experimental results obtained in multiple prostate cancer cell line and xenograft models as well as human primary prostate cancer cells. Each experiment was scientifically designed and rigorously performed with biological and technical repeats. That paper has been highly cited (more than 1150 times) since the publication. Besides that, tumor suppressive functions of miR-34a have also been intensively studied and corroborated in many tumor systems by independent researchers. Since the publication of the original paper, there have been 32 publications that are directly or indirectly in support of the original findings regarding miR-34a and CD44. However, in this Reproducibility Project, the authors are trying to use shoddy data from poorly designed and executed experiments to discredit the original paper. Two of the three experiments in this manuscript were done in only one xenograft model LAPC4. All of the three experiments were one-time experiments with limited number of sample size, which lacks proper biological and technical repeats, especially when they saw big variations within the experimental groups. These points challenge the credibility of the authors\' results, which were obtained via experiments that lacked the basic scientific rigor and could not be used to draw any meaningful conclusions.

Secondly, the LAPC4 cells from the original paper have been validated by cell line authentication in our institute (MD Anderson Cancer Center), and have been intensively used in our lab for more than 12 years. We trust our cells and we are more than willing to provide our LAPC4 cells to them for the in vivo studies.

Thirdly, the authors mentioned that they did not see tumor suppressive function of miR-34a in the LAPC4 model; however, they also mentioned that miR-34a over-expression in the LAPC4 tumor cells was already gone at the endpoint of the tumor experiments. That perfectly explains why they didn\'t see a tumor suppressive function of miR-34a. Using this kind of data to claim that miR-34a lacks tumor suppressive function is merely unacceptable.

Lastly, in the luciferase reporter experiment, there is huge variation in luciferase activity even within one experimental group. It\'s highly unscientific and irresponsible to make any conclusion from this kind of data.

Collectively, publication of this shoddily done \'Reproducibility\' manuscript that lacks the basic scientific rigor will only generate confusions in the field and do a big disservice and damage to the entire scientific community.

10.7554/eLife.43511.018

Author response

Thank you for the evaluation of our manuscript. We would like to thank the reviewers for their attention and insightful commentary. We appreciate their feedback in strengthening this manuscript and welcome the opportunity to publish with *eLife*.

> 1\) Could the replication authors confirm whether their departure from the original conditions used by Liu et al. was approved as part of the original registered protocol? Could the authors elaborate and discuss the path to making this decision and the potential confounds?

The cut-off of CD44 high or CD44 low cells described in the Registered Report, which was informed from the original paper and original authors, was approved at 10%. The departure was not approved as part of the Registered Report and occurred during the course of experimentation. In the revised manuscript we more explicitly state that the deviation was from not only the original paper, but the Registered Report. We also elaborated on the process, specifically the expectation that the cellular population would display CD44 staining along a spectrum that was clearly distinguishable from controls. Instead we found little to no separation of CD44 positive cells from isotype control. Thus, the replication attempt focused on measuring the expression of the target microRNAs in CD44 high (i.e. positive) cells vs CD44 low (i.e. negative) cells. Additionally, considering the hypothesis being tested was reduced miR-34a levels in CD44^+^ cells, the deviation from top 10% to 1% was considered a way to prevent the CD44^-^ population, which was substantially larger, based on staining controls, from masking the reduced levels of the microRNAs in the few CD44^+^ cells observed. That is, if we took the top 10% it would contain 90% CD44^-^ cells and 10% CD44^+^ cells, essentially masking any attempt to observe if there was reduced expression of miR-34a in CD44^+^ cells. While this was a substantial deviation that could mask differences in expression, it is important to note that we observed let-7b levels were reduced in CD44^+^ cells, relative to CD44^-^ cells, as expected and similar to the original study. However, we understand reviewer \#2's concern that this creates a potential confound, particularly in the CD44 low population that could contain CD44 high cells and have included the potential confounds in the revised manuscript.

> 2\) The observation that in the miR-34 over-expression experiment, miR-34 over-expression is lost raises concerns, as described by reviewer \#2. The authors need to address this concern.

We agree with the comments that the loss of miR-34a over-expression, although not through failure of maintaining the sequence as determined by copGFP expression, complicates the interpretation of the experiment. We have incorporated additional discussion in the revised manuscript on the implications of what can be drawn from these results as well as other possible factors (i.e. cell line differences) and mechanisms (i.e. benefit at an early initiation step) that could have influenced this result.

> 3\) Address as much as possible the minor points identified by Referees \#1 and \#3.

We addressed the minor points by Referees \#1 and \#3, with responses listed below.

Reviewer \#1 Minor issues:

> The authors seem to imply that reduced expression of the luciferase reporter carrying the 3\'UTR of CD44 with point mutations disrupting the miR-34a sites could be explained by the fact that the WT 3\'UTR contains a potential miR-141 binding site
>
> overlapping one of the two miR-34a site. Unless there is something I have missed, I find this explanation illogical. If the putative miR-141 site is also disrupted in the mutant 3\'UTR one would expect increased luciferase activity, not reduced (loss of repression by miR-141). The authors should either remove or clarify this sentence.

We removed this sentence in the revised manuscript.

> \"To summarize, we found results that were in the same direction as the original study and not statistically significant where predicted\". This sentence is unclear.

We've revised this sentence to: "To summarize, we found results that were not

consistent in direction with the original study and not statistically significant."

Additionally, this summary sentence, which is included for all Replication Studies as

suggested by eLife, summarizes two key aspects of each experiment - the direction

and statistical significance of each replication result compared to the original study.

Reviewer \#3:

> \[...\] 1) The key issue encountered by the reproducibility study is the cell line of choice. The LAPC4 cell line acquired from the Tang group only exhibited a partial match with the standard LAPC4 profiles in the DSMZ and Cellosaurus database, and more importantly, failed to generate xenograft tumors in NOD/SCID mice. Hence the authors had to acquire cytologically and functionally validated LAPC4 cells from a different source to perform this reproducibility study. This reviewer is wondering if the authors have contacted the Tang group to acquire additional information about the LAPC4 cell lines they had problems with, and made a second request for LAPC4 from the Tang group. It is unclear if the failure to reproduce the original observations is largely due to the cell line difference, or if there exist other contributing factors.

We attempted to reach out to the original authors again, but were informed that work on miR-34a and LAPC4 cells had stopped in the Tang lab and, unfortunately, they could not assist us. The potential confounds of this, specifically cell line genetic drift, have been described in the manuscript.

> 2\) The original study reported a direct regulation between miR-34a and CD44 3\'UTR, but the extent of regulation reflected in luciferase assays was rather modest. Luciferase assays have been widely used to validate a direct regulation of a target mRNA by a miRNA, yet in my opinion, these assays are not very reliable, particularly for miRNA targets that are modestly regulated. Often times, these assays rely on overexpression of both miRNAs and luciferase reporters with wildtype or mutated 3\'UTRs to determine the extent of their direct interactions in cell lines. In addition to the binding between miRNAs and the target 3\'UTR, the relative expression levels between miRNAs and reporter, which often deviates from physiological conditions, play an important role in the results of the assay. Hence, I suggest that the authors include such discussion in their revised manuscript.

We included a brief discussion on some important factors to consider when interpreting results from experiments that overexpress microRNAs in the revised manuscript.

> Minor comments:
>
> 1\) It is not appropriate to claim that \"miR-34a was overexpressed in CD44+ cells, being expressed at 202% of the level in the CD44- 139 cells 140 (Figure 1)\". miR-34a is elevated in level in CD44+ cells, but not necessarily overexpressed. Please be precise when describing this observation.

Thank you for catching this. We have revised this sentence to appropriately describe miR-34a as being elevated, not overexpressed.
